Chitosan-based intragastric delivery of cefuroxime axetil: Development and in-vitro evaluation of mucoadhesive approach

References

• Armstrong AN. 2006. Pharmaceutical experimental esign and interpretation, 2nd ed. Boca Raton, FL: Taylor & Francis Group.
   Google Scholar
• Bodmeier R, Oh KH, Pramar Y. 1989. Preparation and evaluation of drug-containing chitosan beads. Drug Dev Ind Pharm. 15:9:1475–94.
   Web of Science ®Google Scholar
• Bonferoni MC, Sandri G, Rossi S, Ferrari F, Caramella C. 2009. Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin Drug Del. 6:9:923–39.
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia. 2006. Cefuroxime axetil tablet monograph. London: British Pharmacopoeia Commission.
   Google Scholar
• Costa P, Lobo JMS. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 13:123–33.
   PubMed Web of Science ®Google Scholar
• Dhumal RS, Rajname ST, Dhumal ST, Pawar AP. 2006. Design and evaluation of bilayer floating tablets of cefuroxime axetil for bimodal release. J Sci Ind Res. 65:812–16.
   Web of Science ®Google Scholar
• Durkut S, Elcin YM, Elcin EA. 2006. Biodegradation of chitosan-tripolyphosphate beads: In vitro and in vivo studies. Artificial Cell Blood Subst Biotechnol. 34:263–76.
   PubMed Web of Science ®Google Scholar
• Hari PR, Chandy T, Sharma CP. 1996. Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin. J Microencap. 13:3:319–29.
   PubMed Web of Science ®Google Scholar
• Hejazi R, Amiji M. 2003. Chitosan based gastrointestinal delivery systems. J Control Release. 89:151–65.
   PubMed Web of Science ®Google Scholar
• Huguet ML, Neufeld RJ, Dellacherie E. 1996. Calcium-alginate beads coated with polycationic polymers: Comparison of chitosan and DEAE-dextran. Process Biochem. 31:4:347–53.
   Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2003. Stability testing of new drug substances and products Q1A (R2). Current Step 4 version: dated 6 February 2003. Available at: http://www.ich.org/LOB/media/MEDIA419.pdf.
   Google Scholar
• James MB, Elliott LG. 1989. Pharmaceutical composition comprising Cefuroxime Axetil, United States Patent 4,865,851, September 12, 1989.
   Google Scholar
• Jo GH, Yu JH, Yun JH, Hwang SJ, Woo JS. 2002. Preparation of amorphous form of cefuroxime axetil using supercritical fluid processing. Controlled Release Society 29th Annual Meeting Proceedings, Seoul, South Korea, July 20–25, 2002.
   Google Scholar
• Lewis GA, Mathieu D, Phan-Tan-Luu R. 1999. Drugs and the pharmaceutical sciences: Pharmaceutical experimental design. New York, Marcel Dekker Inc.
   Google Scholar
• Mosher GL, McBee J, Shaw DB. 1992. Esterase activity toward the diastereomers of Cefuroxime Axetil in the rat and dog. Pharm Res. 9:5:687–89.
   Google Scholar
• Olivia F, Pierre B, Robert G. 1998. Chitosan: A unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 24:11:979–93.
   Google Scholar
• Patel VF, Patel NM. 2006. Intragastric floating drug delivery system of cefuroxime axetil: In vitro evaluation. AAPS PharmSciTech. 7:1:17:E118–24.
   Web of Science ®Google Scholar
• Patil DA, Patil GB, Deshmukh PK, Belgamwar VS, Fursule RA. 2009. Chitosan coated mucoadhesive multiparticulate drug delivery system for gliclazide. Asian J Pharm Clin Res. 2:2:62–68.
   Google Scholar
• Santus G, Lazzarini C, Bottoni G, Sandefer EP, Page RC, Doll WJ, . 1997. An in vitro, in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm. 44:39–52.
   Web of Science ®Google Scholar
• Siepmann J, Peppas NA. 2001. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Del Rev. 48:139–57.
   PubMed Web of Science ®Google Scholar
• Singh B, Ahuja N. 2000. Book review on pharmaceutical experimental design. Int J Pharm. 195:247–48.
   Google Scholar
• Singla AK, Chawla M. 2001. Chitosan: Some pharmaceutical and biological aspects - An update. J Pharm Pharmacol. 53:1047–67.
   PubMed Web of Science ®Google Scholar
• Somani JK, Bhushan I, Sen H. 2001. Bioavailable oral dosage form of cefuroxime Axetil, United States Patent 6,323,193, November 27, 2001.
   Google Scholar
• Somani VG, Shashi SR, Udavant YK, Atram SC, Satpute R, Shinde MN. 2009. A floating pulsatile drug delivery system based on hollow calcium pectinate beads. Asian J Pharm. 3:120–24.
   Google Scholar
• Sommers DK, Wyk MV, Moncrieff J, Schoeman HS. 1984. Influence of food and reduced gastric acidity on the bioavailability of Bacampicillin and Cefuroxime Axetil. Br J Clin Pharmacol. 18:535–39.
   PubMed Web of Science ®Google Scholar
• Sweetman SC, ed. 2002. Martindale: The Complete Drug Reference, 33rd ed. London: The Pharmaceutical Press, 178.
   Google Scholar
• Talukder R, Fassihi R. 2004. Gastroretentive delivery systems: A mini review. Drug Dev Ind Pharm. 30:10:1019–28.
   Google Scholar
• Woo JS, Chang HC. 2000. Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof. United States Patent 6,107,290. August 22, 2000.
   Google Scholar
• Wozniak T, Hicks J. 1991. Cefuroxime sodium. In: Florey K, ed., Analytical Profiles of Drug Substances. San Diego, CA: Academic Press, 209–237.
   Google Scholar
• Zhou HY, Guang CX, Zhang WF. 2007. In vitro and in vivo evaluation of mucoadhensiveness of chitosan/cellulose acetate multimicrospheres. J Biomed Mater Res A. 83:4:1146–53.
   PubMed Web of Science ®Google Scholar